Amgen Sees Reduced Stake from Van ECK Associates Amid Strong Earnings

Van ECK Associates Corp has reduced its holdings in Amgen Inc. (NASDAQ: AMGN), according to its most recent SEC filing.

The fund owned 188,288 shares of the medical research company's stock after selling 4,827 shares during the period.

Van ECK Associates Corp's holdings in Amgen were worth $68,183,000 at the end of the most recent reporting period.

Other institutional investors have also recently added to or reduced their stakes in the business. Anfield Capital Management LLC increased its position in Amgen by 1,000.0% during the fourth quarter and now owns 77 shares of the medical research company's stock worth $25,000 after acquiring an additional 70 shares.

Amgen has been the subject of a number of research analyst reports. The Goldman Sachs Group set a price objective on shares of Amgen in a research report on Friday, June 5th and BMO Capital Markets boosted their price target on Amgen from $400.00 to $450.00 and gave the company an 'outperform' rating in a research note on Wednesday, August 5th.